Amy Bachrodt is VP at Maze Therapeutics, Inc. (MAZE). They have made 4 open-market trades across 1 company since 2025, most recently 2026-04-01.
CIK 0002050422
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MAZE | 12,965 | $357K |
Shares reported on the most recent Form 4, priced at the 2026-04-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MAZE | SELL · 10b5-1 | 2026-04-01 | 2026-04-02 | $29.44 | $74K | -6.6% | -6.1% | +3.7% |
| MAZE | SELL | 2026-03-02 | 2026-03-03 | $45.20 | $226K | +7.8% | -38.4% | -45.4% |
| MAZE | SELL | 2026-02-02 | 2026-02-04 | $46.04 | $230K | +0.6% | -4.0% | -43.1% |
| MAZE | SELL | 2026-01-22 | 2026-01-26 | $45.52 | $228K | -2.3% | +5.0% | -41.2% |
| MAZE | SELL | 2026-01-02 | 2026-01-06 | $39.15 | $196K | +6.4% | +14.7% | -24.3% |
| MAZE | SELL · 10b5-1 | 2025-12-29 | 2025-12-31 | $40.41 | $606K | +1.3% | +6.7% | -26.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.